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nosed and treated for BC with and without metastases. METHODS: Retrospective 
data from 2 large integrated claims databases spanning July 2008 to December 2010 
were used to identify adult patients with a diagnosis of malignant neoplasm of the 
bladder (ICD-9 188.0–188.9; ICD-10 C67.0–67.9). Patients were included if they (1) had 
continuous eligibility for 6 months prior to at least 6 months following their index 
diagnosis, (2) had no diagnosis of any other cancer in the pre-period, and (3) received 
no chemotherapy in the pre-period. Patients were stratified into 2 cohorts based 
on the presence of metastatic disease within 180 days of diagnosis: non-metastatic 
(NM) and metastatic (M). Resource use and all-cause costs (2013 USD) were evalu-
ated after cancer diagnosis. RESULTS: There were 10,250 (9,268 NM, 982 M) and 
22,965 (20,786 NM, 2,179 M) patients in each of the databases meeting all inclusion 
criteria, respectively. Mean follow-up was 35.1 months and 38.6 months in the 2 
datasets. Total costs 6 months prior to index ranged from $6,497–$6,852 (NM) and 
$6,766–$7,831 (M) and increased to $13,127–$13,559 (NM) and $40,695–$45,817 (M) 
in the 6-month post-index period. The majority of costs in the 6-month post-index 
period were attributable to medical services: NM, 88.7%–91.8%; M, 94.8%–96.5%. 
Inpatient and emergency department costs accounted for 38.2%–40.8% (NM) and 
50.4%–52.5% (M) of total medical costs. CONCLUSIONS: Healthcare costs are high-
est among BC patients with metastatic disease, totaling as much as $45,817 in the 
6-month period after diagnosis. Approximately 50% of costs are related to inpatient 
and emergency department services.
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OBJECTIVES: Due to the paucity of data with respect to real-world costs of care 
among individuals with gastric cancer (GaCa), the objective of this analysis is to evalu-
ate the cost of care among individuals diagnosed with GaCa in 2 large retrospective 
databases. METHODS: Two large integrated claims databases spanning July 2008 to 
September 2012 were used to identify patients ≥ 18 years old diagnosed and treated for 
GaCa. Patients were required to be chemotherapy-naïve, continuously enrolled for ≥ 6 
months pre- and post-diagnosis, and have no other cancer diagnosis at baseline. Eligible 
patients were stratified into cohorts based on the presence and timing of metastasis 
(M) diagnosis: no metastasis (NM), ≤ 120 days (M1), and ≥ 121 days (M2). All costs were 
adjusted to 2013 dollars. RESULTS: There were 5,609 (3,486 NM, 1,469 M1, 654 M2) and 
3,203 (2,004 NM, 875 M1, 324 M2) patients in each of the databases, with 189 and 23, 
respectively, without cost data. Mean follow-up was 24 months in one dataset and 25 
months in the other. Total average monthly costs at baseline were: NM $770–$847; M1 
$662–$773; and M2 $634–$1,020. Total average monthly costs during follow-up were: NM 
$1,631–$2,004; M1 $9,813–$9,945; and M2 $6,598–$8,465. Medical costs represented 86%, 
94%, and 93% of monthly costs for NM, M1, and M2 patients, respectively. Overall, 33% of 
patients received chemotherapy during follow-up and mean monthly chemotherapy-
related costs were $966–$1,109, $2,502–$3,079, and $1,480–$1,521 for NM, M1, and M2, 
respectively. CONCLUSIONS: The results demonstrate the high burden to treat this 
population, with the highest costs in the group with metastases at diagnosis (M1) and 
medical-related costs as a major driver of overall treatment costs.
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OBJECTIVES: A substantial proportion of prostate cancer care is expected to be 
completed in the outpatient hospital setting; however, there is limited informa-
tion on the actual cost of care in this setting. The objective of this analysis was 
to evaluate the total annual costs of treatments for castration-resistant prostate 
cancer (CRPC) with bone metastases for the following agents: cabazitaxel, docetaxel, 
radium 223, and sipuleucel-T. METHODS: An economic model was developed from 
the hospital outpatient perspective with a 1-year time horizon. The expected cost 
of each treatment from the outpatient practice perspective was based on reported 
per-visit treatment costs, professional/administration costs, laboratory/monitoring 
costs, and allocated overhead costs. The total treatment cost per visit was mul-
tiplied by the annual number of expected treatment cycles to calculate annual 
treatment costs. Hospital-specific adverse event (AE) costs were applied to pub-
lished grade 3 and 4 AE rates for each comparator and added to the total cost per 
treatment. RESULTS: The total annual cost of therapy was lowest for docetaxel 
($72,051), followed by radium 223 ($92,489), cabazitaxel ($93,742), and sipuleucel-T 
($101,499). The treatment cost per visit was highest for sipuleucel-T ($30,936), fol-
lowed by radium 223 ($12,362), cabazitaxel ($11,564), and docetaxel ($3,396). AE cost 
were $765 for sipuleucel-T, $5,123 for radium 223, $8,074 for cabazitaxel, and $11,223 
for docetaxel. CONCLUSIONS: Total annual costs for CRPC treatments ranged from 
$72,000 to $101,500 per patient. Docetaxel had the lowest total annual costs, followed 
by radium 223, cabazitaxel, then sipuleucel-T, while sipuleucel-T had the lowest AE 
costs followed by radium 223, cabazitaxel, and docetaxel.
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OBJECTIVES: To establish the cost per month of mean overall survival improve-
ment, in Chilean patients treated with ipilimumab, from a third payer perspec-
adoption from the budget holders. However, if discounts approach 30%, physicians 
are likely to have less influence. CONCLUSIONS: Generally, budget holders and 
clinicians have differing views on the utility and placement of biosimilars in the 
clinical pathway. The uptake of which will ultimately depend on geographies, dis-
counts offered and clinician experience. Biosimilars are not going away, however, 
there are strategies that the originator company can utilize and leverage to delay 
uptake and maintain strong market share.
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OBJECTIVES: Post-thoracotomy pain syndrome (PTPS) is widely reported as one 
of the primary comorbidities following lung resection surgery. The objective of 
this retrospective study was to quantify the clinical and economic burden of post-
thoracotomy pain syndrome (PTPS) following lung resection surgery in the United 
States using a large real-world database. METHODS: This study utilized claims data 
from the Truven MarketScan databases. Adult patients undergoing a lobectomy 
or a segmentectomy as the primary surgical procedure were categorized by the 
surgical approach (video-assisted thoracoscopic surgery (VATS) versus open) and 
primary diagnosis (lung cancer vs. non-lung cancer). The PTPS cohort was identified 
based on a diagnosis of non-neurogenic and neurogenic pain lasting more than 
two months post-operatively. Data were collected for: patient demographics, index 
hospital costs and post-discharge costs. Mean, standard deviation, median values 
are reported for observed differences between the groups. RESULTS: A total of 5,502 
patients (4,898 lung cancer and 604 non-lung cancer) met the study criteria. The 
incidence of PTPS was 5% (n= 261) in the cancer group and 7% (n= 42) in the non-
cancer group. PTPS was more common following open procedures vs VATS (6.1% vs. 
4.6%). The one year observed post-discharge costs were consistently higher in the 
PTPS cohort vs. the non-PTPS cohort for both cancer and non-cancer patients with 
a greater difference of mean values in the cancer group (cancer: $36,872±$23,035 
vs. $31,728±$15,176; non-cancer: $16,497±$9,822 vs. $16,040±$5,988). PTPS patients 
diagnosed in the first two months post-operatively cost more to manage than 
the corresponding non-PTPS cohort (cancer: $39,159±$40,030 vs. $32,302±$50,336; 
non-cancer: $16,584±$14,233 vs. $11,005±$19,371). CONCLUSIONS: Real world data 
shows a lower rate of PTPS in the US when compared to data published in the peer-
reviewed literature, suggesting an under-reporting of PTPS in claims databases. 
PTPS is more common following open procedures and the post-discharge cost of 
managing PTPS patients is higher than non-PTPS patients.
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OBJECTIVES: There is increasing clinical evidence to support the adoption of video 
assisted thoracoscopic surgery (VATS) for lung resection procedures. While the 
frequency of significant intraoperative bleeding requiring follow-up interventions 
is generally low, there is a lack of real-world data quantifying its incidence and 
cost of management. The objective of this retrospective study was to quantify the 
clinical and economic burden of significant bleeding in lung resection surgery in 
the United States. METHODS: This study utilized 2009-2012 data from the Premier 
Perspective DatabaseTM. Adult patients with primary pulmonary lobectomy or 
segmentectomy procedures were categorized by the surgical approach (VATS ver-
sus open) and primary diagnosis (lung cancer (primary or metastatic) vs. non-lung 
cancer). Data were collected for patient demographics, length of stay, cost and 
amount of blood product utilized. Patients requiring ≥ 3 units of blood products 
were categorized as the “significant bleeding” cohort. Those requiring < 3 units 
were the “non-significant bleeding” cohort and those not requiring any blood 
products were the “no bleeding” cohort. A matched cohort analysis was performed 
between the “significant bleeding” and the “non-bleeding cohort” using the follow-
ing matching variables: hospital identifier, lung cancer diagnosis, procedure type 
and gender. RESULTS: A total of 29,737 patients (20,370 in the lung cancer group 
and 9,367 in the non-lung cancer group) met the selection criteria. The matched 
cohort analysis showed a higher cost for the “significant bleeding” cohort vs. 
the “non-bleeding” cohort ($32,140 vs. $19,037). The matched analysis for each 
APR-DRG Severity score showed that the significant bleeding cohort cost more 
for the hospital than the non-bleeding cohort. CONCLUSIONS: Significant chest 
bleeding during lung resection surgery is a rare complication in the US, occur-
ring with a frequency of 0.63%. However, patients with significant intraoperative 
bleeding could cost an average of $13,103 more for the hospital to manage and 
have a longer length of stay.
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OBJECTIVES: Recent systematic literature reviews of bladder cancer (BC) indicated 
that more economic research on management strategies, particularly in the meta-
static setting, is needed. This study evaluated the cost of care among patients diag-
